APP and Alzheimer disease: Therefore, in this study, we treat a clinically relevant mixed murine model of AD and T2D (APP/PS1xdb/db mouse) [21, 22] with EMP from 4 to 26 weeks of age, when both AD and T2D are fully established in our mouse model, to assess the direct effect of long-term EMP treatment on brain pathology.